Grants and Contributions:
Title:
ARP - Design of targeted cancer therapies based on tumour-specific antibodies.
Agreement Number:
1030052
Agreement Value:
$75,000.00
Agreement Date:
Apr 28, 2025 - Mar 31, 2026
Description:
This project involves integrating tumour-specific antibodies into targeted cancer therapies by conjugating them with a chemotoxic agent. These antibody-drug conjugates will then be evaluated for their ability to kill tumour cells.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Quebec, Quebec, CA G1E 3H6
Reference Number:
172-2025-2026-Q1-1030052
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
715580148
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 123 days.
Amendment Date
Sep 4, 2025
Recipient's Operating Name:
9Bio Therapeutics
Recipient's Legal Name:
9489-9002 Québec inc.
Federal Riding Name:
Beauport--Limoilou
Federal Riding Number:
24008
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410
Amendments: